Immutep Limited's Competitiveness

The company operates within the biopharmaceutical industry, specifically in the immunotherapy subsector, which is characterized by significant competition. Competitors include large and specialty pharmaceutical and biotechnology firms, academic research institutions, governmental agencies, and both public and private research organizations. These competitors are developing immune-modulating therapeutics targeting oncology indications such as non-small cell lung cancer, metastatic breast cancer, head and neck squamous cell carcinoma, soft tissue sarcoma, and urothelial cancer. The treatment landscape features anti-PD-(L)1 monotherapies, chemotherapy combinations, targeted therapies for mutations including KRAS, antibody-drug conjugates, anti-TIGIT immuno-oncology agents, and checkpoint inhibitors. In autoimmune diseases, competitors are advancing checkpoint agonists and inhibitory receptor agonists. The company recognizes that many competitors possess substantially greater financial, technical, and human resources, as well as more extensive experience in clinical trials and regulatory approvals, which may affect its competitive position. Competitors identified in company filings include AbbVie, Inc., Aduro Biotech, Inc., Amgen Inc., Arcus Biosciences Inc., AstraZeneca PLC, BioLineRx Ltd., Birdie Biotech, Inc., Checkmate Pharmaceuticals, Inc., Curevac NV, Eisai Co Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Idera Pharmaceuticals, Inc., ImmunityBio, Inc., Immunomedics, Inc., Incyte Corporation, Innate Immunotherapeutics Ltd., Merck & Co., Nektar Therapeutics, Oncosec Medical, Inc., and Regeneron Pharmaceuticals, Inc.